clinical trial · NCT06996080
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
Macular Edema Secondary to InflammationKSI-101Sham Comparator
brief summary
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
started
Jul 16, 2025
primary completion
Dec 1, 2026
completion
Jul 1, 2027
last updated
Sep 12, 2025
official title
A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol